Credit: Shutterstock photoCRISPR Therapeutics AGCRSP was a big mover last session, as the company saw its shares rise more than 12% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company for the company-as the stock is now up 40.1% in the past one-month time frame.
The company has seen a mixed track record when it comes to estimate revisions of one increase and three decrease over the past few weeks, while the Zacks Consensus Estimate for the current quarter hasn't been in the trend either. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
CRISPR Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
CRISPR THERAPTC Price
CRISPR THERAPTC Price | CRISPR THERAPTC Quote
A better-ranked stock in the Medical sector is Akari Therapeutics PLC AKTX , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is CRSP going up? Or down? Predict to see what others think: Up or Down .
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR THERAPTC (CRSP): Free Stock Analysis Report
Akari Therapeutics PLC (AKTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
